FY2028 EPS Estimate for IceCure Medical Decreased by Analyst

Key Points

• Brookline Capital Management has lowered its FY2028 EPS estimate for IceCure Medical from $0.13 to $0.11, while maintaining a "Buy" rating on the stock.
• IceCure Medical reported an EPS of $0.06 for the most recent quarter, exceeding expectations, although its revenue of $0.66 million fell short of the consensus estimate of $0.90 million.
• Institutional ownership in IceCure Medical has increased, with XTX Topco Ltd raising its stake by 123.7% in the fourth quarter.

IceCure Medical Ltd. (NASDAQ:ICCM - Free Report) - Equities research analysts at Brookline Capital Management reduced their FY2028 earnings per share (EPS) estimates for IceCure Medical in a report issued on Wednesday, August 13th. Brookline Capital Management analyst K. Dolliver now forecasts that the company will post earnings per share of $0.11 for the year, down from their previous forecast of $0.13. Brookline Capital Management currently has a "Buy" rating on the stock. The consensus estimate for IceCure Medical's current full-year earnings is ($0.28) per share. Brookline Capital Management also issued estimates for IceCure Medical's FY2029 earnings at $0.26 EPS.

IceCure Medical (NASDAQ:ICCM - Get Free Report) last released its quarterly earnings data on Wednesday, August 13th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.12. IceCure Medical had a negative return on equity of 115.66% and a negative net margin of 317.62%. The company had revenue of $0.66 million during the quarter, compared to the consensus estimate of $0.90 million.

Other equities research analysts also recently issued reports about the company. Loop Capital set a $2.77 price objective on IceCure Medical in a report on Wednesday. Wall Street Zen downgraded IceCure Medical from a "hold" rating to a "sell" rating in a report on Saturday, July 12th. Finally, HC Wainwright reiterated a "buy" rating and issued a $2.00 price objective (down from $2.50) on shares of IceCure Medical in a report on Friday.

IceCure Medical Stock Performance

NASDAQ ICCM traded up $0.04 during trading hours on Friday, hitting $0.89. The company's stock had a trading volume of 283,583 shares, compared to its average volume of 635,233. IceCure Medical has a 12 month low of $0.48 and a 12 month high of $1.66. The company's 50 day simple moving average is $0.98 and its two-hundred day simple moving average is $1.13. The company has a market cap of $51.95 million, a P/E ratio of -5.53 and a beta of 0.32. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.89 and a quick ratio of 1.48.

Institutional Investors Weigh In On IceCure Medical

A hedge fund recently raised its stake in IceCure Medical stock. XTX Topco Ltd raised its position in shares of IceCure Medical Ltd. (NASDAQ:ICCM - Free Report) by 123.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 58,866 shares of the company's stock after purchasing an additional 32,555 shares during the quarter. XTX Topco Ltd owned 0.11% of IceCure Medical worth $65,000 as of its most recent SEC filing. 0.62% of the stock is currently owned by institutional investors.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.